Literature DB >> 22392096

Lung cancer: Maintenance chemotherapy--a stitch in time saves nine?

Rebecca Kirk.   

Abstract

Entities:  

Year:  2012        PMID： 22392096     DOI： 10.1038/nrclinonc.2012.29

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  2 in total

1.  Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.

Authors:  Luis Paz-Ares; Filippo de Marinis; Mircea Dediu; Michael Thomas; Jean-Louis Pujol; Paolo Bidoli; Olivier Molinier; Tarini Prasad Sahoo; Eckart Laack; Martin Reck; Jesús Corral; Symantha Melemed; William John; Nadia Chouaki; Annamaria H Zimmermann; Carla Visseren-Grul; Cesare Gridelli
Journal:  Lancet Oncol       Date:  2012-02-16       Impact factor: 41.316

2.  Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study.

Authors:  Chandra P Belani; Thomas Brodowicz; Tudor E Ciuleanu; Maciej Krzakowski; Sung Hyun Yang; Fábio Franke; Branka Cucevic; Jayaprakash Madhavan; Armando Santoro; Rodryg Ramlau; Astra M Liepa; Carla Visseren-Grul; Patrick Peterson; William J John; Christoph C Zielinski
Journal:  Lancet Oncol       Date:  2012-02-14       Impact factor: 41.316
  2 in total
  1 in total

Review 1.  Minimal residual disease in acute myeloid leukaemia.

Authors:  Christopher S Hourigan; Judith E Karp
Journal:  Nat Rev Clin Oncol       Date:  2013-06-25       Impact factor: 66.675
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.